Udayavni Special

Regulatory nod for conducting clinical trials of Colchicine on COVID-19 patients: CSIR


PTI, Jun 12, 2021, 1:34 PM IST

The Drugs Controller General of India (DCGI) has given approval to the CSIR and Laxai Life Sciences Private Limited to conduct clinical trial of Colchicine on COVID-19 patients, according to a statement on Saturday.

Ram Vishwakarma, the advisor to the CSIR Director General, said Colchicine in combination with standard care will be an important therapeutic intervention for COVID-19 patients with cardiac co-morbidities and also for reducing pro-inflammatory cytokines, leading to faster recovery. A number of global studies have confirmed that cardiac complications during course of COVID-19 infections and post-Covid syndrome are leading to loss of many lives, and it is essential to look for new or repurposed drugs, he said.

”Council of Scientific & Industrial Research (CSIR), and Laxai Life Sciences Pvt Ltd Hyderabad, have been given the regulatory approval by DCGI to undertake a two-arm phase-II clinical trial to assess the safety and efficacy of the drug Colchicine in improvement of clinical outcomes during the treatment of COVID-19 patients,” the statement said. The partner CSIR institutes in this important clinical trial are the CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad and CSIR-Indian Institute of Integrative Medicine (IIIM), Jammu.

India is one of the largest producers of this key drug and if successful, it will be made available to patients at an affordable cost, IICT Director S Chandrasekhar said.

Laxai Life Sciences CEO Ram Upadhayay said the enrolment of patients has already begun at multiple sites across India and the trial is likely to be completed in the next 8-10 weeks. He further added that this drug can be made available to a large population of India based on the results of this trial and regulatory approval.

Last week, the CSIR announced that it along with Laxai Life Sciences Pvt Ltd has initiated phase II clinical trials of anti-helminitic drug Niclosamide for treatment of COVID-19.

Niclosamide has been extensively used in the past for treatment of tapeworm infection in adults as well as children. The safety profile of this drug has been tested over time and has been found safe for human consumption at different dose levels, the CSIR said.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Ram temple to open for ”darshan” to devotees by 2023 end: Sources

All ministers will visit districts to review COVID, flood situation: Bommai

COVID-19: Institutional quarantine mandatory for those who test positive in Udupi

Kundra case: Police question director of firm which developed app

Go First to start flights connecting Doha with three Indian cities from Thursday

Union Minister Anurag Thakur questions Rahul Gandhi’s ‘silence’ on rape incidents in Cong-ruled states

Women’s hockey team played with grit, showcased great skill: PM Modi


Related Articles More

COVID-19: Institutional quarantine mandatory for those who test positive in Udupi

Karnataka logs 1,674 fresh COVID-19 cases, 38 deaths

23,676 new coronavirus cases, 148 more deaths in Kerala

Karnataka sees dip in cases, toll crosses 20,000 mark

Fresh cases drop to 13,984 in Kerala, TPR drops below 11 pc

MUST WATCH

Madhya Pradesh Flood

UDAYAVANI NEWS BULLETIN | August 04-2021

NIA officers raid on former MLA house

FARMER TALKS ABOUT SUICIDES IN AGRICULTURE

How to have healthy Day According to Ayurveda | Udayavani

Latest Additions

Ram temple to open for ”darshan” to devotees by 2023 end: Sources

All ministers will visit districts to review COVID, flood situation: Bommai

COVID-19: Institutional quarantine mandatory for those who test positive in Udupi

Kundra case: Police question director of firm which developed app

Go First to start flights connecting Doha with three Indian cities from Thursday

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.